-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On September 27, the global phase 2 clinical trial of IL-4Rα monoclonal antibody injection (AK120), an innovative drug candidate independently developed by Kangfang Bio for the treatment of moderate to severe atopic dermatitis (AD), has been launched and won the United States FDA's consent
IL-4 and IL-13 are key drivers of type 2 inflammation, and type 2 inflammation plays a major role in diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP)
This is a multi-center, randomized, double-blind, placebo-controlled, parallel grouping, and dose exploration phase 2 clinical study to evaluate the efficacy of AK120 in adult subjects with moderate to severe atopic dermatitis And safety
Previously, AK120 has completed a single-dose escalation phase 1a clinical study in healthy subjects and a multi-dose escalation phase 1b clinical study for the treatment of atopic dermatitis in New Zealand and Australia
According to the preliminary blinded efficacy data of the phase 1b clinical trial, subjects who have achieved the eczema area and severity score (EASI) 50, EASI 75 and the doctor’s overall assessment (IGA) to achieve clean (0) or almost clean (1) improvement were observed The ratio, in each dosing regimen, shows a good effect, and has a good dose dependence
Reference materials:
[1] IL-4Rα monoclonal antibody (AK120) global phase II clinical start for moderate to severe atopic dermatitis.
